Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Humalog KwikPen is a pre-filled insulin delivery device containing insulin lispro, a rapid-acting human insulin analog used to improve glycemic control in adults and children with diabetes mellitus. Insulin lispro begins working within approximately 15 minutes after injection, peaks in about 1 hour, and continues to act for 2 to 4 hours. Humalog KwikPen is designed for ease of use, allowing patients to dial precise doses in 1-unit increments. It is suitable for multiple daily injection regimens, including use with longer-acting basal insulins.
Fact Table | |
Formula | C257H383N65O77S6 (insulin lispro) |
License | US FDA (1996); EMA |
Bioavailability | ~55–77% (subcutaneous) |
Legal status | Prescription only |
Chemical Name | Insulin lispro |
Elimination half-life | ~1 hour |
Dosage (Strength) | 100 units/mL (U-100); also available as U-200 (200 units/mL); 3 mL per pen |
Pregnancy | Category B – considered safe with monitoring |
Brands | Humalog KwikPen, Admelog, generic insulin lispro (varies) |
Protein binding | Negligible |
PubChem CID | 16129678 |
MedlinePlus | a699001 |
ChEBI | CHEBI:80695 |
ATC code | A10AB04 |
DrugBank | DB01306 |
KEGG | D04588 |
Routes of administration | Subcutaneous injection (via KwikPen or vial) |
Humalog should be administered subcutaneously within 15 minutes before a meal or immediately after eating, typically into the abdomen, thigh, upper arm, or buttocks.
Adults and children: Dose individualized based on metabolic needs, blood glucose monitoring, and glycemic targets.
Rotate injection sites to reduce the risk of lipodystrophy.
KwikPens deliver up to 60 units per injection in 1-unit increments.
Do not use if the solution is cloudy, discolored, or contains particles. Use a new needle for each injection. Do not reuse or share pens.
Each mL of Humalog contains:
Insulin lispro 100 units (U-100)
Inactive ingredients include:
Glycerin, metacresol, zinc oxide, and water for injection
KwikPen is also available in U-200 strength (200 units/mL) for patients requiring larger doses.
Humalog is contraindicated in:
Patients experiencing hypoglycemia
Patients with hypersensitivity to insulin lispro or any component of the formulation
Humalog should not be mixed with other insulins in a pen device.
Monitor blood glucose levels frequently, especially when initiating or adjusting therapy.
Changes in insulin regimen, diet, physical activity, or concurrent medications may necessitate dose adjustments.
Use caution in patients with renal or hepatic impairment, as insulin requirements may be reduced.
Avoid intramuscular administration or use during hypokalemia without correction, as insulin can shift potassium intracellularly and increase the risk of hypokalemia.
Potential side effects include:
Hypoglycemia (most common and serious)
Lipodystrophy at injection sites
Allergic reactions (localized or systemic)
Weight gain
Injection site reactions (e.g., redness, swelling)
Rare: anaphylaxis, insulin resistance, or edema